Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$710.94 USD

710.94
827,439

+12.14 (1.74%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $710.01 -0.93 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Nalak Das headshot

5 Safe Stocks to Buy Amid Uncertainty on Wall Street

by Nalak Das

At this juncture, we have narrowed our search to five stocks from defensive sectors like utilities, consumer staples and healthcare. These stocks are: NJR, LW, MCK, PEP, PG.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Granite Ridge (GRNT), Ardmore Shipping (ASC), McKesson (MCK) and Stride (LRN) are well-poised to gain.

Zacks Equity Research

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Zacks Equity Research

Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEV

Zacks Equity Research

Dentsply International (XRAY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

West Pharmaceutical Services (WST) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 16.13% and 0.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights Toll Brothers, Universal Display, Applied Industrial Technologies, PBF Energy and McKesson

by Zacks Equity Research

Toll Brothers, Universal Display, Applied Industrial Technologies, PBF Energy and McKesson have been highlighted in this Screen of The Week article.

Zacks Equity Research

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are Investors Undervaluing McKesson (MCK) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Santanu Roy headshot

5 Stocks Backed by High Efficiency to Boost Portfolio Returns

by Santanu Roy

Invest in companies like Toll Brothers (TOL), Universal Display (OLED), Applied Industrial Technologies (AIT), PBF Energy (PBF) and McKesson (MCK) to make the most of their higher efficiency levels.

Zacks Equity Research

Here's Why McKesson (MCK) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on robust volume growth in the Plasma business and upbeat guidance.

Zacks Equity Research

Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow

by Zacks Equity Research

Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.

Zacks Equity Research

Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye

by Zacks Equity Research

Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.

Zacks Equity Research

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Zacks Equity Research

Should Value Investors Buy Henry Schein (HSIC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

PacBio's (PACB) New Offering to Boost WGS Data Analysis

by Zacks Equity Research

PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.

Zacks Equity Research

3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

Zacks Equity Research

Best Momentum Stocks to Buy for October 17th

by Zacks Equity Research

SP, MCK and EMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 17, 2023.

Zacks Equity Research

Zacks.com featured highlights Stride, Deckers Outdoor, Molina Healthcare and McKesson

by Zacks Equity Research

Stride, Deckers Outdoor, Molina Healthcare and McKesson have been highlighted in this Screen of The Week article.

Sumit Singh headshot

4 Stocks That Flaunt an Impressive Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. LRN, DECK, MOH and MCK and are sound enough to meet financial obligations.

Zacks Equity Research

Here's Why You Should Retain Fresenius Medical (FMS) for Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.